SHANGHAI & CAMBRIDGE, Mass. / Aug 22, 2024 / Business Wire / Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in September 2024:
Morgan Stanley 22nd Annual Global Healthcare Conference
Location: New York, New York
Cantor Fitzgerald Global Healthcare Conference
Fireside Chat: Thursday, September 19, 2024, 8:00 a.m. ET in Track 2
Location: New York, New York
About Zai Lab
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious diseases, and neuroscience. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.
For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.
| Last Trade: | US$31.08 |
| Daily Change: | -1.43 -4.40 |
| Daily Volume: | 653,958 |
| Market Cap: | US$3.390B |
April 25, 2025 April 23, 2025 April 21, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
